Our data are in agreement with previous evidence indicating that GO likely binds to integrins at the cancer cell’s plasma membrane, activating the integrin-FAK-Rho-ROCK pathway and rendering cancer cells more susceptible to chemotherapeutic agents [67]. Here, PTK2 is linked to cancer.